Please provide your email address to receive an email when new articles are posted on . Any bleeding event regardless of severity can adversely impact a patient. Factor XI and XIa inhibitors in ...
Concomitant use of SSRIs and OACs was associated with a 33% increased risk for major bleeding. Among patients with atrial fibrillation (AF), concomitant use of selective serotonin reuptake inhibitors ...
Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...
In the CKD population treated with oral anticoagulants for atrial fibrillation, major bleeding is more likely in male patients and those with congestive heart failure, vascular disease, and a history ...
Two of three commonly prescribed non-vitamin K oral anticoagulants (NOACs)—dabigatran and apixaban—have similar rates of major bleeding compared with aspirin, a large systematic review and ...
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ -- Data ...
The population-based study from the U.K. showed that taking an SSRI and OAC (both direct OACs and vitamin K antagonists [VKAs]) together was associated with a 33% increased risk of major bleeding ...
Please provide your email address to receive an email when new articles are posted on . Rivaroxaban was linked to higher rates of major bleeding compared with low-dose aspirin. Apixaban and dabigatran ...
In patients undergoing revascularization for left main coronary artery disease, CABG is associated with higher rates of all bleeds and in-hospital major bleeding, while PCI is linked to more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback